Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.60 |
| ▸ | NPC1 | O15118 | 5/20 | 0.60 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | LIPE | Q05469 | 7/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.53 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.48 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7479368 | 0.82 | LIPE (0.68) | SMN1; SMN2NPC1RAB9ATP53LIPE | |
| SCHEMBL14890641 | 0.78 | LIPE (0.62) | SMN1; SMN2NPC1RAB9ATP53LIPE | |
| SCHEMBL7456919 | 0.78 | LIPE (0.61) | SMN1; SMN2NPC1RAB9ATP53LIPE | |
| SCHEMBL7488907 | 0.78 | LIPE (0.61) | SMN1; SMN2NPC1RAB9ATP53LIPE | |
| SCHEMBL11881512 | 0.78 | LIPE (0.61) | SMN1; SMN2NPC1RAB9ATP53LIPE | |
| SCHEMBL8961559 | 0.77 | TP53 (0.57) | SMN1; SMN2NPC1RAB9ATP53KDM4E | |
| SCHEMBL12010892 | 0.75 | SMN1; SMN2 (0.78) | SMN1; SMN2TP53KDM4EALOX15ALDH1A1 | |
| SCHEMBL30515325 | 0.75 | RAB9A (1.00) | SMN1; SMN2NPC1RAB9ATP53ALDH1A1 | |
| SCHEMBL10226339 | 0.75 | RAB9A (1.00) | SMN1; SMN2NPC1RAB9ATP53ALDH1A1 | |
| SCHEMBL7549708 | 0.75 | LIPE (1.00) | SMN1; SMN2NPC1RAB9ATP53LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964213-B1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN INC (US) | 2020-11-04 | — | — | EP | disclosed |
| EP-2646030-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3,4- DIHYDROISOQUINOLIN-2(1 H)-YL-3-PHENYLUREA DERIVATIVES HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY | Allergan, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| EP-2646030-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3,4- DIHYDROISOQUINOLIN-2(1 H)-YL-3-PHENYLUREA DERIVATIVES HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY | Allergan, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| US-8507560-B2 | Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1H)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity | ALLERGAN, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507560-B2 | Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1H)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity | ALLERGAN, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507560-B2 | Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1H)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity | ALLERGAN, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| WO-2012074785-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3,4- DIHYDROISOQUINOLIN-2(1 H)-YL-3-PHENYLUREA DERIVATIVES HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY | ALLERGAN, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012074785-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3,4- DIHYDROISOQUINOLIN-2(1 H)-YL-3-PHENYLUREA DERIVATIVES HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY | ALLERGAN, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142726-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3,4-DIHYDROISOQUINOLIN-2(1H)-YL-3-PHENYLUREA DERIVATIVES HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142726-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3,4-DIHYDROISOQUINOLIN-2(1H)-YL-3-PHENYLUREA DERIVATIVES HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142726-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3,4-DIHYDROISOQUINOLIN-2(1H)-YL-3-PHENYLUREA DERIVATIVES HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY | FPR1, FPR3, FPR2 | SMN1; SMN2 2568/4885NPC1 892/4885RAB9A 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.